Looking to bolster its overseas presence, drug major Lupin is scouting for acquisition opportunities in the US market, especially in inhalers and injectables segments.
“We continue to evaluate opportunities and going forward acquisitions in the US would have to satisfy our multiple aspirations of creating a meaningful speciality business, bolstering our existing brands business and acquiring technological capabilities that we would like to work on,” Lupin Ltd CFO S Ramesh told PTI.
The company continues to be on the lookout for meaningful targets, be it brands or technology companies, in inhalation, complex injectables and skin diseases segments, he added.
Help employers find you! Check out all the jobs and post your resume.
